• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿毒症中的血小板功能障碍。II. 花生四烯酸对二磷酸腺苷或胶原所致纤维蛋白原受体暴露受损的纠正作用。

Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen.

作者信息

Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace M J, Martinez J, Murphy S

出版信息

J Lab Clin Med. 1986 Sep;108(3):246-52.

PMID:3018111
Abstract

Previous studies showed that platelets from patients with uremia have a marked decrease in their aggregation response to adenosine diphosphate (ADP) and collagen as single agents or as a pair. It is known that small amounts of arachidonic acid can enhance the sensitivity of platelets to concentrations of ADP or collagen that do not cause aggregation when used singly. Stimulation of platelets by certain agonists induces the formation of fibrinogen receptors on the platelet surface. The binding of fibrinogen that follows is essential for platelet aggregation. The platelet membrane glycoprotein IIb-IIIa complex appears to be the site of the fibrinogen receptor. Therefore, we investigated the binding of iodine 125-labeled fibrinogen to uremic platelets exposed to ADP, collagen, or arachidonic acid as single agents and as pairs. When aggregation and binding were studied in response to ADP, collagen, or the combination of ADP with collagen, uremic platelets had reduced aggregation and bound abnormally low amounts of fibrinogen. In contrast, platelets from patients with uremia bound as much 125I-fibrinogen and aggregated as well as controls when ADP or collagen were used in combination with low concentrations of arachidonic acid. Studies with a monoclonal antibody (B 79.7) suggested that the number of glycoprotein IIb-IIa molecules is the same in uremic and normal platelets. We conclude that uremia impairs the exposure of fibrinogen receptors on platelets in response to ADP or collagen without affecting the glycoprotein IIb-IIa complex quantitatively. Correction by arachidonic acid of the impaired aggregation and exposure of fibrinogen receptors by ADP or collagen suggests that abnormal release of endogenous arachidonic acid plays a role in the dysfunction of platelets in uremia.

摘要

以往研究表明,尿毒症患者的血小板对二磷酸腺苷(ADP)和胶原蛋白单独或联合使用时的聚集反应明显降低。已知少量花生四烯酸可增强血小板对单独使用时不会引起聚集的ADP或胶原蛋白浓度的敏感性。某些激动剂刺激血小板会诱导血小板表面形成纤维蛋白原受体。随后纤维蛋白原的结合对于血小板聚集至关重要。血小板膜糖蛋白IIb-IIIa复合物似乎是纤维蛋白原受体的所在部位。因此,我们研究了125碘标记的纤维蛋白原与暴露于ADP、胶原蛋白或花生四烯酸单独及联合使用的尿毒症血小板的结合情况。当研究对ADP、胶原蛋白或ADP与胶原蛋白组合的聚集和结合反应时,尿毒症血小板的聚集减少,纤维蛋白原结合量异常低。相比之下,当ADP或胶原蛋白与低浓度花生四烯酸联合使用时,尿毒症患者的血小板结合的125I-纤维蛋白原量与对照组相同,聚集情况也相同。用单克隆抗体(B 79.7)进行的研究表明,尿毒症血小板和正常血小板中糖蛋白IIb-IIa分子的数量相同。我们得出结论,尿毒症会损害血小板对ADP或胶原蛋白反应时纤维蛋白原受体的暴露,但不会定量影响糖蛋白IIb-IIa复合物。花生四烯酸对ADP或胶原蛋白导致的聚集受损和纤维蛋白原受体暴露的纠正表明,内源性花生四烯酸的异常释放参与了尿毒症患者血小板功能障碍。

相似文献

1
Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen.尿毒症中的血小板功能障碍。II. 花生四烯酸对二磷酸腺苷或胶原所致纤维蛋白原受体暴露受损的纠正作用。
J Lab Clin Med. 1986 Sep;108(3):246-52.
2
Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex.胶原蛋白、花生四烯酸和二磷酸腺苷对血小板纤维蛋白原结合位点的暴露:糖蛋白IIb-IIIa复合物单克隆抗体的抑制作用
Blood. 1983 Jan;61(1):140-8.
3
Fibrinogen fragments and platelet dysfunction in uremia.尿毒症中的纤维蛋白原片段与血小板功能障碍
Kidney Int. 1999 Jul;56(1):299-305. doi: 10.1046/j.1523-1755.1999.00518.x.
4
Ca+2 mobilization and fibrinogen binding of platelets refractory to adenosine diphosphate stimulation.对二磷酸腺苷刺激无反应的血小板的钙离子动员和纤维蛋白原结合
J Lab Clin Med. 1985 Aug;106(2):111-22.
5
Increased binding of fibrinogen to platelets in diabetes: the role of prostaglandins and thromboxane.糖尿病中纤维蛋白原与血小板结合增加:前列腺素和血栓素的作用。
Blood. 1985 Jan;65(1):156-62.
6
Exposure of fibrinogen receptors on fresh and stored platelets by ADP and epinephrine as single agents and as a pair.通过ADP和肾上腺素单独及联合作用使新鲜血小板和储存血小板上的纤维蛋白原受体暴露。
Blood. 1983 Jun;61(6):1054-9.
7
Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis.尿毒症中的血小板功能障碍。多方面缺陷可通过透析部分纠正。
Am J Med. 1985 Nov;79(5):552-9. doi: 10.1016/0002-9343(85)90051-8.
8
Aggregation of chymotrypsin-treated thrombasthenic platelets is mediated by fibrinogen binding to glycoproteins IIb and IIIa.经胰凝乳蛋白酶处理的血小板无力症血小板的聚集是由纤维蛋白原与糖蛋白IIb和IIIa结合介导的。
J Lab Clin Med. 1985 Dec;106(6):651-60.
9
Dynamics of platelet glycoprotein IIb-IIIa receptor expression and fibrinogen binding. II. Quantal activation parallels platelet capture in stir-associated microaggregation.血小板糖蛋白IIb-IIIa受体表达及纤维蛋白原结合的动力学。II. 定量激活与搅拌相关微聚集过程中的血小板捕获平行。
Biophys J. 1994 Nov;67(5):2069-75. doi: 10.1016/S0006-3495(94)80690-3.
10
Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors.二磷酸腺苷(ADP)诱导人血小板生成血栓素A2需要通过整合素α(IIb)β3和ADP受体进行协调信号传导。
Blood. 2002 Jan 1;99(1):193-8. doi: 10.1182/blood.v99.1.193.

引用本文的文献

1
A Case of Limb-Threatening Hematoma in a Patient Taking Citalopram and Apixaban Concurrently.一例同时服用西酞普兰和阿哌沙班的患者出现危及肢体的血肿病例。
Cureus. 2021 Nov 20;13(11):e19771. doi: 10.7759/cureus.19771. eCollection 2021 Nov.
2
Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease.心肌梗死后慢性肾脏病患者双联抗血小板治疗的安全性。
J Am Heart Assoc. 2019 May 21;8(10):e012236. doi: 10.1161/JAHA.119.012236.
3
Successful kidney transplantation normalizes platelet function.
成功的肾移植可使血小板功能恢复正常。
Clin Kidney J. 2018 Aug;11(4):574-580. doi: 10.1093/ckj/sfx148. Epub 2018 Jan 17.
4
First reported case series in the United States of hemopericardium in patients on apixaban.美国首次报道的阿哌沙班治疗患者发生心包积血的病例系列。
HeartRhythm Case Rep. 2017 Dec 11;4(2):82-84. doi: 10.1016/j.hrcr.2017.11.015. eCollection 2018 Feb.
5
Evaluating safety of thrombolysis in chronic kidney disease patients presenting with pulmonary embolism using propensity score matching.采用倾向评分匹配评估慢性肾脏病伴发肺栓塞患者溶栓治疗的安全性。
J Thromb Thrombolysis. 2017 Oct;44(3):324-329. doi: 10.1007/s11239-017-1545-6.
6
Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.西洛他唑治疗在无症状外周动脉疾病血液透析患者中的作用:一项回顾性队列研究。
Biomed Res Int. 2016;2016:8236903. doi: 10.1155/2016/8236903. Epub 2016 Sep 22.
7
Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions.接受经皮冠状动脉介入治疗的血液透析患者的抗血小板治疗
Nephrourol Mon. 2015 Jul 22;7(4):e28099. doi: 10.5812/numonthly.28099. eCollection 2015 Jul.
8
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.管理慢性肾脏病患者的心血管风险:随机对照试验证据的综述。
Ther Adv Chronic Dis. 2011 Jul;2(4):265-78. doi: 10.1177/2040622311401775.
9
Spontaneous renal hemorrhage in hemodialysis patients.血液透析患者的自发性肾出血
Case Rep Nephrol Urol. 2011 Jul;1(1):1-6. doi: 10.1159/000330192. Epub 2011 Aug 8.
10
Pulmonary embolism in patients with CKD and ESRD.慢性肾脏病和终末期肾病患者的肺栓塞。
Clin J Am Soc Nephrol. 2012 Oct;7(10):1584-90. doi: 10.2215/CJN.00250112. Epub 2012 Jul 26.